OSI licenses OSI-774 to Roche, DNA

OSIP licensed its OSI-774 oral EGF receptor inhibitor to Roche (SWX:ROCZ) and Genentech (DNA). OSIP and DNA will share costs and profits from U.S. commercialization, and ROCZ will be responsible for p...